FDA Recalls NAD+ Injection Due to Sub-Potency and Stability Concerns
Olympia Compounding Pharmacy is recalling NAD+ Nicotinamide Adenine Dinucleotide injection vials nationwide due to sub-potency or exceeded reconstitution time.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for sub-potency and reconstitution/stability issues affecting a prescription drug. The rubric limits Class II recalls without hospitalization reports to High severity rather than Severe.
Plain-English summary
Olympia Compounding Pharmacy is recalling NAD+ Nicotinamide Adenine Dinucleotide lyophilized powder for injection due to sub-potency or exceeded reconstitution time. The recalled product is a multi-dose 500 mg vial formulation distributed nationwide, including Puerto Rico.
The affected lots are D24005 (expiration 4/5/22) and C41008 (expiration 3/8/22). A total of 2634 vials have been distributed. The product is dispensed by prescription only.
Sub-potency means the medication contains less active ingredient than labeled, which could affect treatment effectiveness. Exceeded reconstitution time may indicate the product does not remain stable after mixing with diluent.
If you have received this product, contact your healthcare provider or pharmacist for guidance. Do not use the recalled medication without first consulting a healthcare professional.
The recalled product
- Product
- NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose 500 mg per vial, Each ML contains: 0.288% Sodium Phosphate Monobasic USP, 0.42% Sodium Phosphate Dibasic USP, 5% Mannitol USP, Sterile Water for Injection USP, Rx Only, Olympia…
- Category
- Drug — Compounded Injectable
- Affected units
- 2,634
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: D24005 Exp. 4/5/22
- C41008 Exp. 3/8/22
Distribution
Part of a larger recall action
This product is one of 7 recalled by Olympia Compounding Pharmacy dba Olympia Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same manufacturer · Olympia Compounding Pharmacy dba Olympia Pharmacy
See all →- HighLidocaine 2% injectable solution recalled for lack of sterility assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Compounded Papaverine Injection Due to Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighFDA Recalls Testosterone Cypionate Injection Vials for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighCompounded pharmaceutical vials recalled due to sterility assurance failure
FDA (Drugs) · 2022-06-01
- HighOndansetron Hydrochloride vials recalled due to sterility assurance concerns
FDA (Drugs) · 2022-06-01
Same hazard · sub potency
See all →- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- LowSinuFrin Nasal Decongestant Recalled for Sub-Potency Nationwide
FDA (Drugs) · 2024-07-03
- SeverePrescription Drug Javygtor Recalled for Sub-Potency and Powder Discoloration
FDA (Drugs) · 2024-05-15
Similar recalls
- HighFDA recalls NAD+ pharmaceutical powder vials due to sterility concerns
FDA (Drugs) · 2022-06-01
- HighFDA recalls NAD+ powder due to failed reconstitution
FDA (Drugs) · 2022-05-04
- HighNAD+ Compounded Drug Recall for Manufacturing Quality Control Violations
FDA (Drugs) · 2022-05-04
- SevereWells Pharmacy Recalls NADH Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- HighInjectable drug recalled for lack of sterility assurance
FDA (Drugs) · 2022-06-01
- HighNAD+ injection recalled across all lots for lack of sterility assurance
FDA (Drugs) · 2025-10-15